CG Scientific

CG Scientific Inc. is a private, early-stage biotech company dedicated to creating a breakthrough treatment for type 1 diabetes. The company operates from its headquarters in Worcester, Massachusetts, and is actively seeking investment opportunities to advance its novel therapeutic approach. While specific details about its technology platform and pipeline remain undisclosed on its public website, the company's mission centers on addressing the significant unmet medical need in autoimmune diabetes treatment. CG Scientific represents a promising venture in the competitive diabetes therapeutics landscape.

Undisclosed novel therapeutic strategy focused on treating the underlying cause of type 1 diabetes, likely involving immunomodulation, cell therapy, or a related biological approach.

Total raised: $3.5M

CG Scientific competes in the crowded type 1 diabetes therapeutic space against companies like Vertex Pharmaceuticals (cell therapy), Sanofi/Provention Bio (immunomodulation with Tzield), and numerous other biotechs. Differentiation will require demonstrating a superior mechanism of action, efficacy, or safety profile compared to these established approaches.